click below
click below
Normal Size Small Size show me how
PHAR 517
Chemotherapy - drug class
Term | Definition |
---|---|
methotrexate | antimetabolite (antifolate) |
pemetrexed | antimetabolite (antifolate) |
5-FU | antimetabolite (antipyrimidine) |
capecitabine | antimetabolite (antipyrimidine) |
cytarabine (Ara-c) | antimetabolite (antipyrimidiine) |
gemcitabine | antimetabolite (antipyrimidine) |
6-MP - mercaptopurine | antimetabolite (antipurine) |
fludarabine | antimetabolite (antipurine) |
cladribine | antimetabolite (antipurine) |
clofarabine | antimetabolite (antipurine) |
hydroxyurea | antimetabolite |
vincristine | antimicrotubule (vinca alkaloid) |
vinblastine | antimicrotubule (vinca alkaloid) |
vinorelbine | antimicrotubule (vinca alkaloid) |
paclitaxel | antimicrotubule (taxanes) |
nab-paclitaxel | antimicrotubule (taxanes) |
docetaxel | antimicrotubule (taxanes) |
irinotecan | topoisomerase I inhibitor |
topotecan | topoisomerase I inhibitor |
etoposide | topoisomerase II inhibitor |
bleomycin | misc |
L-asparaginase | misc |
peg-asparaginase | misc |
Erwinia-asparaginase | misc |
everolimus | mTOR inhibitor |
temsirolimus | mTOR inhibitor |
chlorambucil | alkylating agent (nitrogen mustard) |
cyclophosphamide | alkylating agent (nitrogen mustard) |
ifosfamide | alkylating agent (nitrogen mustard) |
bendamustine | alkylating agent (nitrogen mustard) |
dacarbazine | alkylating agent (nitrogen mustard) |
cisplatin | alkylating agent (platinum) |
carboplatin | alkylating agent (platinum) |
oxaliplatin | alkylating agent (platinum) |
decitabine | alkylating agent (hypomethylating agent) |
daurorubicin | anthracycline |
doxorubicin | anthracycline |
idarubicin | anthracycline |
epirubicin | anthracycline |
rituximab | mAB - CD20 (chimeric) |
trastuzumab | mAB - HER-2 (humanized) |
pertuzumab | mAB - HER-2 (humanized) |
cetuximab | mAB - EGFR (chimeric) |
bevacizumab | mAB - VEGF ligand (humanized) |
pembrolizumab | mAB - PD-1 receptor (humanized) |
nivolumab | mAB - PD-1 receptor (human) |
cemiplimab | mAB - PD-1 receptor (human) |
dostarlimab | mAB - PD-1 receptor (human) |
atezolizumab | mAB - PD-L1 ligand (humanized) |
durvalumab | mAB - PD-L1 ligand (human) |
avelumab | mAB - PD-L1 (human) |
imatinib | tyrosine kinase inhibitor (BCR-ABL) |
desatinib | tyrosine kinase inhibitor (BCR-ABL) |
nilotinib | tyrosine kinase inhibitor (BCR-ABL) |
bosutinib | tyrosine kinase inhibitor (BCR-ABL) |
ponatinib | tyrosine kinase inhibitor (BCR-ABL) |
erlotinib | tyrosine kinase inhibitor (EGFR) |
osimertinib | tyrosine kinase inhibitor (EGFR) |
alectinib | tyrosine kinase inhibitor (ALK) |
brigatinib | tyrosine kinase inhibitor (ALK) |
lorlatinib | tyrosine kinase inhibitor (ALK) |
dabrafenib | tyrosine kinase inhibitor (BRAF) |
olaparib | PARP inhibitor |
niraparib | PARP inhibitor |
talazoparib | PARP inhibitor |
bortezomib | proteasome inhibitor |
carfilzomib | proteasome inhibitor |
thalidomide | immunomodulator |
lenalidomide | immunomodulator |